Vetpharma is the veterinary division of Chemo, part of the Insud Pharma group, providing Animal Health solutions. We are located in Barcelona, where the group was founded in 1977.
In Vetpharma we are a highly qualified team.
We have extensive experience in development, registration and marketing veterinary medicinal products, API’s and nutraceuticals.
Veterinary medicines in several pharmaceutical forms for livestock and companion animals. Our finished products are of the best quality, manufactured in Europe according to Good Manufacturing Practices (GMP) and distributed following GDP (Good Distribution Practices).
Our dossiers for registration comply with the requirements of the most exigent regulatory agencies. Vetpharma holds more than 500 Marketing Authorizations within the EU.
We supply from our warehouse in Barcelona Active Principle Ingredients (APIs) intended for animal health products which are manufactured by Chemo and our partners. Our products meet the most demanding requirements (DMF, CEP, EP, USP).
Nutraceuticals are dietary supplements intended to improve the animals’ health, welfare and productivity. Vetpharma has developed a wide range of nutraceuticals suitable for in-feed or water inclusion with highly positive therapeutic effects.
With more than 40 years’ experience, Insud Pharma has become an established, global group in the pharmaceutical industry, with a continuous growth and diversification.
It has a presence at every echelon of the chemical-pharmaceutical industry through Chemo, Exeltis and mAbxience.
We are committed to Quality, being at the heart of what we do. To us, Quality is everybody’s responsibility.
Chemo is a global leader in R&D and manufacturing for over 100 value-added active pharmaceutical ingredients and more than 50 medicines with over 200 different product presentations. We produce our own APls, as well as our own formulation patents for all major treatment areas. Our veterinary division, Vetpharma, is specialised in animal healthcare.
Exeltis is a leading player in branded medicines with strategic focus on Women’s Health. Today Exeltis is a top player in this segment and the company has expanded into other physician therapeutic areas including Central Nervous System, Respiratory, Dermatology and Ophthalmology.
mAbxience is a biotechnology company specialised in the research, development and manufacture of biosimilar monoclonal antibodies. mAbxience operates around the world via robust commercial relationships with local partners, all leaders in their markets.